Currently Viewing:
Newsroom
Currently Reading
Opdivo Approved to Treat Metastatic SCLC
August 17, 2018 – Samantha DiGrande
This Week in Managed Care: August 10, 2018
August 10, 2018
MD Anderson, PALISI Jointly Develop Pediatric Guidelines for CAR T-Cell Therapy
August 09, 2018 – Samantha DiGrande
Liquid Biopsy Identifies Patients More Likely to Benefit From Immunotherapy in NSCLC
August 07, 2018 – Samantha DiGrande
FDA Accepts First Allogeneic CAR T-Cell Therapy Trial
August 04, 2018 – Samantha DiGrande
Opdivo Approved for Adjuvant Treatment of Melanoma in European Union
August 02, 2018 – Samantha DiGrande
Cytokine "Backpacks" for T Cells Increase Immune Response in Solid Tumors
July 26, 2018 – Samantha DiGrande
Pembrolizumab Meets Primary End Point in Phase 3 Head and Neck Cancer Trial
July 25, 2018 – Samantha DiGrande
Men With Advanced Cancers Respond Better Than Women to Immune Checkpoint Inhibitors
July 20, 2018 – Samantha DiGrande

Opdivo Approved to Treat Metastatic SCLC

Samantha DiGrande
Announced today, Bristol-Myers Squibb’s nivolumab (Opdivo) has received FDA approval as the first immuno-oncology treatment for patients with metastatic small-cell lung cancer (SCLC) whose cancer has progressed after platinum-based chemotherapy and at least 1 other line of treatment.
Announced today, Bristol-Myers Squibb’s nivolumab (Opdivo) has received FDA approval as the first immuno-oncology treatment for patients with metastatic small-cell lung cancer (SCLC) whose cancer has progressed after platinum-based chemotherapy and at least 1 other line of treatment.

SCLC accounts for about 10% to 15% of all lung cancers. In the United States alone, about 27,000 cases of SCLC are expected to be diagnosed in 2018. “We recognize the critical need to provide patients with cancer therapies that may offer more durable responses—particularly for those living with hard-to-treat, aggressive diseases like small cell lung cancer,” said Sabine Maier, MD, development lead, thoracic cancers at Bristol-Myers Squibb, in a statement.  

Click here to learn more about immuno-oncology treatments for lung cancer.
The treatment was granted priority review by the FDA, subsequently followed by an approval under the accelerated approval pathway based on overall response rate and duration of response. However, continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trials.

The approval was based on data from the ongoing phase 1/2 Checkmate-032 study that is investigating nivolumab in patients who experienced disease progression following platinum-based chemotherapy. The trial enrolled 109 patients into the nivolumab arm and found that 12% (n = 13; 95% CI, 6.5-19.5) responded to treatment based on assessment by a Blinded Independent Central Review, regardless of PD-L1 expression. Of the 13 patients who responded, 12 experienced a partial response and 1 patient had a complete response.

The median duration of response was 17.9 months (95% CI, 7.9-42.1; range, 3-42.1 months). Nivolumab was discontinued in 10% of patients, and serious adverse events occurred in 45% of participants. The most frequent adverse events reported in at least 2% of patients were pneumonia, dyspnea, pneumonitis, pleural effusion, and dehydration.

“While immuno-oncology innovations have dramatically changed how oncologists approach certain cancers, we have had limited progress for patients with small cell lung cancer,” said Leora Horn, MD, MSc, director of the thoracic oncology program at Vanderbilt University Medical Center, in a statement. “Today’s approval of nivolumab is particularly exciting considering it is the first checkpoint inhibitor approved for these specific patients, and now we can finally treat this devastating disease from a different angle.”


 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up